Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AQSTNASDAQ:ARCTNASDAQ:RANINASDAQ:SLDB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$2.79+1.1%$2.78$2.20▼$5.80$277.11M2.021.46 million shs1.38 million shsARCTArcturus Therapeutics$10.98-3.5%$11.96$8.04▼$45.00$297.79M2.36449,954 shs349,690 shsRANIRani Therapeutics$0.73-5.9%$1.27$0.72▼$7.47$41.96M0.25745,551 shs386,028 shsSLDBSolid Biosciences$2.77$3.85$2.45▼$10.99$214.68M2.32992,389 shs2.16 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics+1.10%-8.17%+16.24%-6.93%-10.70%ARCTArcturus Therapeutics+3.93%-8.96%+27.72%-29.71%-58.18%RANIRani Therapeutics-7.80%-28.22%-27.55%-49.47%-89.26%SLDBSolid Biosciences+6.95%-24.11%+3.75%-3.82%-72.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAQSTAquestive Therapeutics1.551 of 5 stars3.62.00.00.02.60.00.0ARCTArcturus Therapeutics2.6649 of 5 stars4.60.00.00.02.02.50.6RANIRani Therapeutics1.9048 of 5 stars3.63.00.00.00.01.70.6SLDBSolid Biosciences3.5405 of 5 stars3.74.00.00.02.03.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAQSTAquestive Therapeutics 3.14Buy$10.67282.32% UpsideARCTArcturus Therapeutics 3.13Buy$59.20439.16% UpsideRANIRani Therapeutics 3.20Buy$12.001,543.84% UpsideSLDBSolid Biosciences 3.33Buy$15.67465.58% UpsideCurrent Analyst Ratings BreakdownLatest RANI, ARCT, AQST, and SLDB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.004/3/2025RANIRani TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/2/2025AQSTAquestive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/13/2025SLDBSolid BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.00 ➝ $11.003/10/2025ARCTArcturus TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.003/10/2025AQSTAquestive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/10/2025ARCTArcturus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $68.003/10/2025SLDBSolid BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$16.00 ➝ $20.003/7/2025AQSTAquestive TherapeuticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$7.003/7/2025AQSTAquestive TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/7/2025AQSTAquestive TherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.00(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAQSTAquestive Therapeutics$57.56M4.81N/AN/A($1.59) per share-1.75ARCTArcturus Therapeutics$138.39M2.15N/AN/A$10.42 per share1.05RANIRani Therapeutics$1.03M40.82N/AN/A$0.51 per share1.43SLDBSolid Biosciences$8.09M26.54N/AN/A$6.27 per share0.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAQSTAquestive Therapeutics-$7.87M-$0.52N/AN/AN/A-59.75%N/A-33.96%5/12/2025 (Estimated)ARCTArcturus Therapeutics-$29.73M-$3.01N/AN/AN/A-36.39%-22.39%-14.81%5/12/2025 (Estimated)RANIRani Therapeutics-$33.97M-$1.06N/AN/AN/AN/A-219.64%-56.71%5/12/2025 (Estimated)SLDBSolid Biosciences-$96.01M-$3.04N/AN/AN/AN/A-58.75%-47.84%5/13/2025 (Estimated)Latest RANI, ARCT, AQST, and SLDB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025SLDBSolid Biosciences-$0.53N/AN/AN/AN/AN/A5/12/2025Q1 2025AQSTAquestive Therapeutics-$0.17N/AN/AN/A$12.23 millionN/A5/12/2025Q1 2025ARCTArcturus Therapeutics-$1.10N/AN/AN/A$25.64 millionN/A5/12/2025Q1 2025RANIRani Therapeutics-$0.22N/AN/AN/AN/AN/A3/31/2025Q4 2024RANIRani Therapeutics-$0.24-$0.27-$0.03-$0.27N/A$1.03 million3/6/2025Q4 2024ARCTArcturus Therapeutics-$0.33-$1.11-$0.78-$1.11$44.64 million$22.77 million3/5/2025Q4 2024AQSTAquestive Therapeutics-$0.14-$0.19-$0.05-$0.19$13.11 million$11.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAQSTAquestive TherapeuticsN/AN/AN/AN/AN/AARCTArcturus Therapeutics$0.716.51%N/AN/A N/ARANIRani TherapeuticsN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAQSTAquestive TherapeuticsN/A6.375.91ARCTArcturus TherapeuticsN/A4.764.76RANIRani Therapeutics2.341.601.60SLDBSolid BiosciencesN/A7.857.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAQSTAquestive Therapeutics32.45%ARCTArcturus Therapeutics94.54%RANIRani Therapeutics30.19%SLDBSolid Biosciences81.46%Insider OwnershipCompanyInsider OwnershipAQSTAquestive Therapeutics8.35%ARCTArcturus Therapeutics15.30%RANIRani Therapeutics53.30%SLDBSolid Biosciences1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAQSTAquestive Therapeutics16099.32 million84.02 millionOptionableARCTArcturus Therapeutics18027.12 million22.94 millionOptionableRANIRani Therapeutics11057.48 million26.75 millionOptionableSLDBSolid Biosciences10077.50 million35.05 millionOptionableRANI, ARCT, AQST, and SLDB HeadlinesRecent News About These CompaniesSolid Biosciences Inc. (NASDAQ:SLDB) Given Average Rating of "Buy" by BrokeragesMay 4, 2025 | marketbeat.comWhy Solid Biosciences Inc.’s (SLDB) Stock Is Up 10.82%May 3, 2025 | aaii.comSolid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of "Buy" by BrokeragesMay 2, 2025 | americanbankingnews.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2025 | globenewswire.comSolid Biosciences to Present Phase 1/2 Trial Data for SGT-003 Gene Therapy at ASGCT 2025 Annual MeetingMay 1, 2025 | nasdaq.comSolid Biosciences to Participate at The Citizens Life Sciences ConferenceApril 30, 2025 | globenewswire.comSolid Biosciences to Present at the American Society of Gene and Cell Therapy’s 28th Annual MeetingApril 29, 2025 | finance.yahoo.comSolid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual MeetingApril 29, 2025 | globenewswire.comResearch Analysts Set Expectations for SLDB Q1 EarningsApril 26, 2025 | marketbeat.comWalleye Capital LLC Sells 233,270 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)April 25, 2025 | marketbeat.comJPMorgan Chase & Co. Purchases 945,863 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)April 22, 2025 | marketbeat.comTrexquant Investment LP Purchases 139,851 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)April 14, 2025 | marketbeat.comSolid Biosciences Inc. (NASDAQ:SLDB) Shares Sold by ADAR1 Capital Management LLCApril 9, 2025 | marketbeat.comSolid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy SpaceApril 8, 2025 | seekingalpha.comCan Solid Biosciences Challenge Sarepta in the DMD Market?April 8, 2025 | marketbeat.comSolid Biosciences reports inducement grants under Nasdaq listing ruleApril 2, 2025 | markets.businessinsider.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2025 | globenewswire.comWhy Solid Biosciences Inc.’s (SLDB) Stock Is Down 14.97%April 1, 2025 | aaii.comTruist Financial Keeps Their Buy Rating on Solid Biosciences (SLDB)March 21, 2025 | markets.businessinsider.comSolid Biosciences Inc. (SLDB): Among Top Insider Purchases Last MonthMarch 14, 2025 | insidermonkey.comSolid Biosciences (SLDB) Receives a Buy from J.P. MorganMarch 12, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeatGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitBy Chris Markoch | April 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to BenefitGold Is Making All-Time Highs, But So Is This Quiet MetalBy Gabriel Osorio-Mazilli | April 21, 2025View Gold Is Making All-Time Highs, But So Is This Quiet MetalRANI, ARCT, AQST, and SLDB Company DescriptionsAquestive Therapeutics NASDAQ:AQST$2.79 +0.03 (+1.09%) As of 04:00 PM EasternAquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Arcturus Therapeutics NASDAQ:ARCT$10.98 -0.40 (-3.51%) As of 04:00 PM EasternArcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Rani Therapeutics NASDAQ:RANI$0.73 -0.05 (-5.93%) As of 04:00 PM EasternRani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.Solid Biosciences NASDAQ:SLDB$2.77 0.00 (0.00%) As of 03:52 PM EasternSolid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend What the ExtraHop Deal Means for CrowdStrike DoorDash’s Uptrend Is Gaining Momentum in 2025 Why Flutter Entertainment May Be a Resilient Sports Betting Stock OXY Stock Rebound Begins Following Solid Earnings Beat Is Energy Transfer Undervalued or a Value Trap? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
